The Urologic Oncology Journal was founded 25 years ago and we reviewed the literature since that time in the area of urothelial cancer to see the progress and pitfalls we have made over this time period. A comprehensive literature search was conducted by the authors involved who are all actively involved in research, clinical trials, and treatment for urothelial cancer and the results were summarized over the past 25 years. The field of urothelial cancer has evolved tremendously in the last 25 years with the incorporation of molecular subtyping, novel imaging, immunotherapy, and robotic surgery. However, treatments such as BCG and radical cystectomy have remained steadfast over the last 25 years. Although we have a better understanding of the biology of bladder cancer, we still have a long way from being able to cure patients with bladder cancer and eliminate morbidity from treatments. Nevertheless, considerable progress has been made since the founding of the Urologic Oncology Journal 25 years ago.

《泌尿肿瘤学杂志》创刊于 25 年前，我们回顾了自那时以来在尿路上皮癌领域的文献，以了解我们在此期间取得的进展和缺陷。所有积极参与尿路上皮癌研究、临床试验和治疗的作者进行了全面的文献检索，并对过去 25 年的结果进行了总结。在过去的 25 年中，随着分子分型、新型成像、免疫疗法和机器人手术的结合，尿路上皮癌领域取得了巨大的发展。然而，在过去的 25 年中，卡介苗和根治性膀胱切除术等治疗方法一直很稳定。虽然我们对膀胱癌的生物学有了更好的了解，我们距离治愈膀胱癌患者和消除治疗中的发病率还有很长的路要走。尽管如此，自 25 年前《泌尿肿瘤学杂志》创刊以来，已经取得了相当大的进展。